Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Among authors: querol l. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.
Villarrubia N, Rodríguez-Martín E, Alari-Pahissa E, Aragón L, Castillo-Triviño T, Eixarch H, Ferrer JM, Martínez-Rodríguez JE, Massot M, Pinto-Medel MJ, Prada Á, Rodríguez-Acevedo B, Urbaneja P, Gascón-Gimenez F, Herrera G, Hernández-Clares R, Salgado MG, Oterino A, San Segundo D, Cuello JP, Gil-Herrera J, Cámara C, Gómez-Gutiérrez M, Martínez-Hernández E, Meca-Lallana V, Moga E, Muñoz-Calleja C, Querol L, Presas-Rodríguez S, Teniente-Serra A, Vlagea A, Muriel A, Roldán E, Villar LM. Villarrubia N, et al. Among authors: querol l. Clin Chim Acta. 2019 Jan;488:135-142. doi: 10.1016/j.cca.2018.11.008. Epub 2018 Nov 5. Clin Chim Acta. 2019. PMID: 30408481
Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB. Saposnik G, et al. Among authors: querol l. Mult Scler Relat Disord. 2024 Oct;90:105838. doi: 10.1016/j.msard.2024.105838. Epub 2024 Aug 23. Mult Scler Relat Disord. 2024. PMID: 39216454
Long-lasting treatment effect of rituximab in MuSK myasthenia.
Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I. Díaz-Manera J, et al. Among authors: querol l. Neurology. 2012 Jan 17;78(3):189-93. doi: 10.1212/WNL.0b013e3182407982. Epub 2012 Jan 4. Neurology. 2012. PMID: 22218276 Clinical Trial.
149 results